A dynamic model of COVID-19 infection quantifies the impact of preventive interventions on the infection of severely immunocompromised subjects in the United Kingdom

• Carmen Pin ,

  Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft

  * E-mail: carmen.pin@astrazeneca.com

  Affiliation Systems Medicine, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom

  https://orcid.org/0000-0001-8734-6167

  ⨯
• Sylvia Taylor,

  Roles Conceptualization, Funding acquisition

  Affiliation Medical and Scientific Affairs, Vaccines & Immune Therapies, Biopharmaceuticals, AstraZeneca, Cambridge, United Kingdom

  ⨯
• Catia Ferreira,

  Roles Conceptualization, Funding acquisition

  Affiliation Medical and Scientific Affairs, Vaccines & Immune Therapies, Biopharmaceuticals, Wilmington, United States of America

  ⨯
• Sofie Arnetorp,

  Roles Conceptualization, Funding acquisition

  Affiliation Health Economics, BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden

  ⨯
• Holly Kimko

  Roles Conceptualization, Investigation, Writing – review & editing

  Affiliation Systems Medicine, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, United States of America

  ⨯